Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$76,966.00-1.21%ETH$2,263.06-1.08%GOLD$3,916.30-1.34%OIL$98.51+2.13%
Smart Investors Daily
SID Premium
DR

NASDAQ · DRUG

Bright Minds Biosciences Inc.

Healthcare · Biotechnology

$26.20

Down-$28.78 (-52.35%)

Updated Nov 3, 2026, 12:10 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
630.71M
P/E ratio
-97.49
Dividend yield
0.00%
52-week range
$18.90 – $92.39
Volume
1.83M
Avg. volume
145.82K

Price performance · DRUG

DRUG price history

1M range · 0 trading sessions · Daily adjusted prices

DRUG does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest DRUG news

The latest Smart Investors Daily articles mentioning DRUG.

Stock researchCompany · Overview

DRUG research

Overview

Company profile and research snapshot.

Company profile

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$82.50
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Bright Minds Biosciences And 2 More Canadian Biotech Stocks

Oil prices are climbing again as shipping attacks in the Gulf raise fresh worries about inflation and higher interest rates that can pressure many sectors. Canadian biotech stocks sit slightly off to the side of this drama, with product pipelines tied more to medical science than to energy cycles. That disconnect can appeal right now. This article highlights three Canadian biotech ideas identified by our quality focused screener. The three Canadian biotech stocks below are just a starting...

Yahoo · Sep 30, 2026

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the P

Yahoo · Sep 30, 2026

Auxly Cannabis Group And 2 Other Canadian Biotech Stocks To Watch

Bond yields have surged to levels last seen before the global financial crisis, which makes future cash flows harder to value and puts every growth story under a harsher spotlight. That pressure has not spared Canadian biotech shares, yet it also filters out weaker balance sheets and stretched valuations. This article highlights 3 Canadian biotechnology stocks from our quality focused screener that could merit a closer look today. The three stocks below are a small sample of what screens well...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By